Syncona Portfolio Company Achilles Therapeutics to Pursue Voluntary Liquidation
Syncona's board has decided that its portfolio company, Achilles Therapeutics, will pursue a members' solvent voluntary liquidation to return capital to shareholders. Shareholders are expected to receive between 1.20 and 1.32 pounds per share, pending approval at a general meeting on March 20. Syncona holds 11,086,909 American depositary shares in Achilles, valued at 8.5 million pounds as of September 30, 2024.
Syncona said Wednesday the board of its portfolio company Achilles Therapeutics decided to pursue a members' solvent voluntary liquidation and return capital to shareholders.
Achilles shareholders are expected to receive between 1.20 pounds sterling and 1.32 pounds per share based on currently available information. The proposed voluntary liquidation and capital distribution are subject to the approval of shareholders at a March 20 general meeting.
The life science investor owns 11,086,909 American depositary shares representing the same number of shares in Achilles. The holding value of the stake was 8.5 million pounds as of Sept. 30, 2024.
